Clinical Trial

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Study acronym: PROTECT IV
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health after a heart procedure compared to the current standard of care.
Protocol Amendment History 2 changes
notable Trial sites expanded: 99 -> 110 locations 2026-07-29
notable Primary completion pushed: 2026-03 -> 2026-10 2026-07-29
Trial Details
NCT Number NCT04763200
Lead Sponsor Abiomed Inc.
Conditions Left Ventricular Dysfunction, Coronary Artery Disease
Enrollment 1,252 participants
Start Date 2021-04-13
Primary Completion 2026-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-28